Ravi V Shah1, Matthew A Allison2, João A C Lima3, David A Bluemke4, Siddique A Abbasi5, Pamela Ouyang3, Michael Jerosch-Herold6, Jingzhong Ding7, Matthew J Budoff8, Venkatesh L Murthy9. 1. Department of Cardiology and Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. 2. Department of Family and Preventative Medicine, University of California-San Diego, San Diego, CA, United States. 3. Cardiology Division, Johns Hopkins Medical Institute, Baltimore, MD, United States. 4. Radiology and Imaging Sciences, National Institutes of Health Clinical Center, National Institute of Biomedical Imaging and Bioengineering, United States. 5. Department of Cardiology and Medicine, Brown University, Providence, RI, United States. 6. Non-Invasive Cardiovascular Imaging, Brigham and Women's Hospital, Boston, MA, United States. 7. Department of Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States. 8. Department of Cardiology and Medicine, University of California-Los Angeles, Los Angeles, CA, United States. 9. Department of Medicine (Cardiovascular Medicine Division) and Department of Radiology (Nuclear Medicine Division), University of Michigan, Ann Arbor, MI, United States. Electronic address: vlmurthy@med.umich.edu.
Abstract
BACKGROUND AND AIMS: To balance competing cardiovascular benefits and metabolic risks of statins, markers of type 2 diabetes (T2D) susceptibility are needed. We sought to define a competing risk/benefit of statin therapy on T2D and cardiovascular disease (CVD) events using liver attenuation and coronary artery calcification (CAC). METHODS AND RESULTS: 3153 individuals from the Multi-Ethnic Study of Atherosclerosis (MESA) without CVD, T2D/impaired fasting glucose, or baseline statin therapy had CT imaging for CAC and hepatic attenuation (hepatic steatosis). Cox models and rates of CVD and T2D were calculated to assess the role of liver attenuation in T2D and the relative risks/benefits of statins on CVD and T2D. 216 T2D cases were diagnosed at median 9.1 years follow-up. High liver fat and statin therapy were associated with diabetes (HR 2.06 [95%CI 1.52-2.79, P < 0.0001] and 2.01 [95%CI 1.46-2.77, P < 0.0001], respectively), after multivariable adjustment. With low liver fat and CAC = 0, the number needed to treat (NNT) for statin to prevent one CVD event (NNT 218) was higher than the number needed to harm (NNH) with an incident case of T2D (NNH 68). Conversely, those with CAC >100 and low liver fat were more likely to benefit from statins for CVD reduction (NNT 29) relative to T2D risk (NNH 67). Among those with CAC >100 and fatty liver, incremental reduction in CVD with statins (NNT 40) was less than incremental risk increase for T2D (NNH 24). CONCLUSIONS: Liver fat is associated with incident T2D and stratifies competing metabolic/CVD risks with statin therapy. Hepatic fat may inform T2D surveillance and lipid therapeutic strategies.
BACKGROUND AND AIMS: To balance competing cardiovascular benefits and metabolic risks of statins, markers of type 2 diabetes (T2D) susceptibility are needed. We sought to define a competing risk/benefit of statin therapy on T2D and cardiovascular disease (CVD) events using liver attenuation and coronary artery calcification (CAC). METHODS AND RESULTS: 3153 individuals from the Multi-Ethnic Study of Atherosclerosis (MESA) without CVD, T2D/impaired fasting glucose, or baseline statin therapy had CT imaging for CAC and hepatic attenuation (hepatic steatosis). Cox models and rates of CVD and T2D were calculated to assess the role of liver attenuation in T2D and the relative risks/benefits of statins on CVD and T2D. 216 T2D cases were diagnosed at median 9.1 years follow-up. High liver fat and statin therapy were associated with diabetes (HR 2.06 [95%CI 1.52-2.79, P < 0.0001] and 2.01 [95%CI 1.46-2.77, P < 0.0001], respectively), after multivariable adjustment. With low liver fat and CAC = 0, the number needed to treat (NNT) for statin to prevent one CVD event (NNT 218) was higher than the number needed to harm (NNH) with an incident case of T2D (NNH 68). Conversely, those with CAC >100 and low liver fat were more likely to benefit from statins for CVD reduction (NNT 29) relative to T2D risk (NNH 67). Among those with CAC >100 and fatty liver, incremental reduction in CVD with statins (NNT 40) was less than incremental risk increase for T2D (NNH 24). CONCLUSIONS: Liver fat is associated with incident T2D and stratifies competing metabolic/CVD risks with statin therapy. Hepatic fat may inform T2D surveillance and lipid therapeutic strategies.
Authors: Philip Greenland; Joseph S Alpert; George A Beller; Emelia J Benjamin; Matthew J Budoff; Zahi A Fayad; Elyse Foster; Mark A Hlatky; John McB Hodgson; Frederick G Kushner; Michael S Lauer; Leslee J Shaw; Sidney C Smith; Allen J Taylor; William S Weintraub; Nanette K Wenger; Alice K Jacobs; Sidney C Smith; Jeffrey L Anderson; Nancy Albert; Christopher E Buller; Mark A Creager; Steven M Ettinger; Robert A Guyton; Jonathan L Halperin; Judith S Hochman; Frederick G Kushner; Rick Nishimura; E Magnus Ohman; Richard L Page; William G Stevenson; Lynn G Tarkington; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2010-12-14 Impact factor: 24.094
Authors: Naveed Sattar; David Preiss; Heather M Murray; Paul Welsh; Brendan M Buckley; Anton J M de Craen; Sreenivasa Rao Kondapally Seshasai; John J McMurray; Dilys J Freeman; J Wouter Jukema; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G Westendorp; James Shepherd; Barry R Davis; Sara L Pressel; Roberto Marchioli; Rosa Maria Marfisi; Aldo P Maggioni; Luigi Tavazzi; Gianni Tognoni; John Kjekshus; Terje R Pedersen; Thomas J Cook; Antonio M Gotto; Michael B Clearfield; John R Downs; Haruo Nakamura; Yasuo Ohashi; Kyoichi Mizuno; Kausik K Ray; Ian Ford Journal: Lancet Date: 2010-02-16 Impact factor: 79.321
Authors: C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins Journal: Lancet Date: 2010-11-08 Impact factor: 79.321
Authors: Ravi V Shah; Amanda Anderson; Jingzhong Ding; Matthew Budoff; Oliver Rider; Steffen E Petersen; Majken Karoline Jensen; Manja Koch; Matthew Allison; Nadine Kawel-Boehm; Jessica Wisocky; Michael Jerosch-Herold; Kenneth Mukamal; João A C Lima; Venkatesh L Murthy Journal: JACC Cardiovasc Imaging Date: 2017-03-15
Authors: Hideo Makimura; Takara L Stanley; Caroline Suresh; Ana Luisa De Sousa-Coelho; Walter R Frontera; Stephanie Syu; Laurie R Braun; Sara E Looby; Meghan N Feldpausch; Martin Torriani; Hang Lee; Mary-Elizabeth Patti; Steven K Grinspoon Journal: J Clin Endocrinol Metab Date: 2015-12-21 Impact factor: 5.958
Authors: Haroon Kamran; Eric Kupferstein; Navneet Sharma; Jocelyne G Karam; Alyson K Myers; Irini Youssef; James R Sowers; Deborah R Gustafson; Moro O Salifu; Samy I McFarlane Journal: Cardiorenal Med Date: 2018-01-22 Impact factor: 2.041
Authors: Luis A Rodriguez; Alka M Kanaya; Stephen C Shiboski; Alicia Fernandez; David Herrington; Jingzhong Ding; Patrick T Bradshaw Journal: Ann Epidemiol Date: 2021-07-19 Impact factor: 3.797
Authors: Luis A Rodriguez; Stephen C Shiboski; Patrick T Bradshaw; Alicia Fernandez; David Herrington; Jingzhong Ding; Ryan D Bradley; Alka M Kanaya Journal: J Gen Intern Med Date: 2021-01-26 Impact factor: 6.473
Authors: Till Ittermann; Henry Völzke; Muhammad Naeem; Robin Bülow; Sabine Schipf; Nicole Werner; Marcus Dörr; Markus M Lerch; Jens-Peter Kühn; Wolfgang Rathmann; Matthias Nauck; Marcello Ricardo Paulista Markus Journal: Sci Rep Date: 2021-06-24 Impact factor: 4.379